Top in endocrinology: Tirzepatide outperforms semaglutide; FDA rejects GLP-1 implant
Click Here to Manage Email Alerts
Tirzepatide led to greater HbA1c and body weight reductions compared with placebo or semaglutide in people with type 2 diabetes, according to a meta-analysis of randomized trials.
The analysis of tirzepatide, which is marketed as Mounjaro (Eli Lilly), and semaglutide, marketed as Wegovy (Novo Nordisk), will be presented at the European Association for the Study of Diabetes annual meeting.
It was the top story in endocrinology last week.
The second top story was about an FDA committee that unanimously voted to reject an implantable device that would deliver a GLP-1 receptor agonist in adults with type 2 diabetes.
Read these and more top stories in endocrinology below:
Tirzepatide outperforms semaglutide for HbA1c reduction, weight loss in type 2 diabetes
Tirzepatide induced greater HbA1c and body weight reductions vs. placebo than semaglutide for people with type 2 diabetes, according to data that will be presented at the European Association for the Study of Diabetes annual meeting. Read more.
FDA committee unanimously rejects GLP-1 implant for type 2 diabetes
In a hearing on Sept. 21, an FDA committee rejected an implantable device capable of delivering a GLP-1 receptor agonist for adults with type 2 diabetes. Read more.
Latent autoimmune diabetes may increase risk for complications vs. type 2 diabetes
Adults with type 2 diabetes using a fully closed-loop automated insulin delivery system have a higher time in range than those receiving conventional insulin therapy, according to findings published in Diabetic Medicine. Read more.
Automated insulin delivery may be feasible for hospitalized adults with diabetes
Automated insulin delivery with remote real-time continuous glucose monitoring may be feasible for managing glucose among hospitalized adults with diabetes, according to findings from a small study. Read more.
Clinical pharmacist visits improve HbA1c for Hispanic adults with type 2 diabetes
Hispanic adults with type 2 diabetes who attended a primary care clinic visit with a clinical pharmacist had a larger drop in HbA1c than those who received usual care, according to a study published in JAMA Network Open. Read more.